Pharming Group (NASDAQ:PHAR – Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $8.12, but opened at $7.86. Pharming Group shares last traded at $7.86, with a volume of 161 shares changing hands.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday, August 1st.
Get Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The business had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same quarter in the previous year, the firm earned $0.02 earnings per share. Research analysts forecast that Pharming Group will post -0.03 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,435 shares of the company’s stock after buying an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
- Five stocks we like better than Pharming Group
- Airline Stocks – Top Airline Stocks to Buy Now
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- What are earnings reports?
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- What is a Dividend King?
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.